In vitro efficacy of frozen erythrocytes: implementation of new strategic blood stores to alleviate resource shortage (issue revisited).

Turkish journal of medical sciences

PubMedID: 26281332

Cetinkaya RA, Yilmaz S, Eker I, Ünlü A, Uyanik M, Tapan S, Pekoglu A, Pekel AA, Ertas Z, Gürsel O, Musabak UH, Yilmaz S, Avci IY, Çetin AT, Eyigün CP. In vitro efficacy of frozen erythrocytes: implementation of new strategic blood stores to alleviate resource shortage (issue revisited). Turk J Med Sci. 2015;45(3):638-43.
BACKGROUND/AIM
Currently, the provision of blood products largely depends on walking blood banks and limited amounts of stored blood with short shelf lives. We aimed to compare the efficacy of erythrocyte concentrate (ECs) by pre- and postfreezing in vitro tests.

MATERIALS AND METHODS
In our study, 10 ECs were glycerolized, frozen, thawed, and then deglycerolized using the Naval Blood Research Laboratory method. In addition to using the standard tests, ATP and 2,3-DPG levels and the viability of erythrocytes were also determined.

RESULTS
The prefreezing mean viability rates of erythrocytes changed from 89.7 ± 13.7% to 98.6 ± 1.8% after thawing and deglycerolization. Prefreezing and day 0 ATP levels (1.64 ± 0.15 µmol/g Hb and 1.81 ± 0.14 µmol/g Hb, respectively) were similar. The 2,3-DPG levels decreased from 18.09 ± 4.78 µmol/g Hb measured before the procedure to 10.41 ± 4.58 µmol/g Hb on day 0. The mean hemolysis rates and supernatant Hb levels changed from 0.21 ± 0.11% to 0.36 ± 0.12% and 1 ± 0.5 g/L to 1.5 ± 0.5 g/L, respectively.

CONCLUSION
The test results showed the efficacy of the frozen-thawed ECs to be used in humans for a broad spectrum of clinical indications. As a part of a contingency plan, national frozen blood reserves need to be established.